Skip to Main Content

Article / Publication

November 11, 2022
CGM Technology and Digital Health
Article / Publication

Lilly’s new Tempo personalized diabetes management platform features a reusable medical device that attaches to prefilled, disposable insulin pens and sends dose-related data to a compatible app. Patients attach the Tempo Smart Button to the Tempo Pen to send insulin-dose information to TempoSmart. Capturing the data facilitates medication reminders, personalized education resources, and feedback on blood glucose levels, realized through integration with compatible technologies, including real-time continuous glucose monitoring (RT-CGM) via the Dexcom G6. Labeled a “diabetes ecosystem” solution, the fully integrated combination of devices, drugs, and technology offers an opportunity to adapt to each patient’s unique needs in diabetes management while providing value to both physician and payer stakeholders at the same time.

Learn More
Share:
November 11, 2022
Clinical Outcomes
Article / Publication

The Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) randomized clinical trial (RCT) featured a 26-week phase comparing real-time continuous glucose monitoring (RT-CGM) with blood glucose monitoring (BGM) in 203 adults aged ≥60 years with type 1 diabetes (T1D). Of the 198 participants who completed the RCT, 98% of RT-CGM group participants continued (CGM-CGM cohort) and 98% of BGM group participants crossed over to CGM (BGM-CGM cohort) for an additional 26 weeks. In the BGM-CGM cohort, median time <70 mg/dL decreased from 3.9% to 1.9% (P<0.001), TIR increased from 56% to 60% (P=0.006) and HbA1c decreased from 7.5% to 7.3% (P=0.025). Severe hypoglycemic events were reported for 9 participants while using BGM during the RCT and for only 2 participants during the extension phase with RT-CGM (P=0.02), indicating a sustained benefit of hypoglycemia avoidance in older adults out to 12 months.

Miller KM, et al. Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022;24(6):424-434.

Learn More
Share:
November 9, 2022
Clinical Outcomes
Article / Publication

This feasibility study of critically ill patients with COVID19 in a single medical ICU (MICU) wearing Dexcom G6 concluded real-time continuous glucose monitoring (RT-CGM) systems can be successfully implemented in the MICU using a hybrid protocol implementation approach. Nurses indicated RT-CGM provided an overall time savings and decreased the time spent in COVID19 rooms

Faulds ER, et al. Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring (CGM) in Critically Ill Patients With COVID-19. Endocr Pract. 2021;27(4):354-361.

Learn More
Share:
November 9, 2022
Clinical Outcomes
Article / Publication

This randomized control trial (RCT) of 185 general medicine and surgery patients with Type 1 and Type 2 diabetes found real-time continuous glucose monitoring (RT-CGM) safe and effective for guiding insulin therapy in hospitalized patients treated with a basal-bolus insulin regimen compared with a point-of-care (POC) group with blinded CGM and POC-guided insulin adjustments. RT- CGM resulted in a similar improvement in glycemic control and a significant reduction of recurrent hypoglycemia among patients with one or more hypoglycemic events compared with POC group.  

Spanakis, EK et al. Continuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients with Diabetes: A Randomized Clinical Trial. Diabetes Care. Diabetes Care. 2022;45(10):2369-2375.

Learn More
Share:
November 9, 2022
Clinical Outcomes
Article / Publication

This publication describes a retrospective analysis of an inpatient real-time continuous glucose monitoring (RT-CGM) program at a community hospital and the accuracy of the system. Authors concluded RT-CGM for inpatient diabetes monitoring is feasible, is a reliable comparator to POC (point-of-care) testing, prevents adverse patient outcomes through safe and timely treatment decisions, and poses minimal risk when used for management decisions. A corresponding podcast is available below.

Baker M, et al. Practical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes. Am J Health Syst Pharm. 2022;79(6):452-458.

Learn More
Share:
November 9, 2022
Clinical Outcomes
Article / Publication

A clinical practice guideline for inpatient hyperglycemia management from the Endocrine Society was published in The Journal of Clinical Endocrinology & Metabolism. The guideline focuses on hyperglycemia management in non-critically ill hospitalized patients and highlights the use of emerging diabetes technology, including real-time continuous glucose monitoring (RT-CGM), for glycemic management in the hospital. Based on available evidence, the guideline recommends use of RT-CGM with confirmatory point-of-care (POC) testing for insulin dosing decisions in adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia. 

Korytkowski M, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101-2128.  

Learn More
Share:
October 3, 2022
Population Health
Article / Publication

Source: Population Health Management

Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.

Learn More
Share:
September 11, 2022
CGM Technology and Digital Health
Article / Publication

The US Food and Drug Administration (FDA) approved the Omni Pod 5 tubeless insulin pump technology for individuals aged 2 years and older with type 1 diabetes (T1D). Omnipod 5 is the first tubeless, wearable automated insulin delivery (AID) system that integrates with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system and a compatible smartphone to automatically adjust insulin and help protect against both hyper- and hypoglycemia.

Learn More
Share: